Who Paid My Doc
Jeremie Calais
Nuclear Imaging & Therapy Los Angeles, CA Medical Doctor
NPI 1053927079 CMS profile 8279666
200 Medical Plaza Suite B114, Ste B114, Los Angeles, CA 90095
General payments
$130,660
Research payments
$21,980
Ownership & investment interest
$0
Research they led as principal investigator
$12,606,100
Through program year 2025, Jeremie Calais of Los Angeles, CA is reported in the CMS Open Payments database as having received $130,660 across 74 general payments and $21,980 in research payments paid to them. Separately, studies naming them as principal investigator received $12,606,100 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $39,012 | 14 | |
| 2025 | Research | $6,657 | 4 | |
| 2024 | General | $24,736 | 17 | |
| 2024 | Research | $7,613 | 1 | |
| 2023 | General | $30,854 | 19 | |
| 2023 | Research | $3,553 | 1 | |
| 2022 | General | $25,294 | 16 | |
| 2022 | Research | $4,157 | 1 | |
| 2021 | General | $7,600 | 5 | |
| 2020 | General | $3,163 | 3 |
Beside peers
- Jeremie Calais
- Nuclear Imaging & Therapy median
- Middle half of Nuclear Imaging & Therapy
- National median
In program year 2025, general payments to Jeremie Calais were reported at $39,012. Among 36 Nuclear Imaging & Therapy profiles paid that year, the median was $122 and the middle half received between $44 and $626.
Show as a table
| Year | Jeremie Calais | Nuclear Imaging & Therapy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $125 | $75–$435 | $163 |
| 2020 | $3,163 | $115 | $38–$1,233 | $114 |
| 2021 | $7,600 | $62 | $16–$343 | $132 |
| 2022 | $25,294 | $123 | $47–$287 | $149 |
| 2023 | $30,854 | $106 | $56–$169 | $160 |
| 2024 | $24,736 | $62 | $21–$161 | $164 |
| 2025 | $39,012 | $122 | $44–$626 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
81 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nuclear Imaging & Therapy in California
John Linfoot
Nuclear Imaging & Therapy · Lafayette, CA
Maria Guevara
Nuclear Imaging & Therapy · North Hollywood, CA
Holly Marciniak Thompson
Nuclear Imaging & Therapy · Santa Clara, CA
Frederick Weiland
Nuclear Imaging & Therapy · Roseville, CA
Chiayi Ni
Nuclear Imaging & Therapy · Sylmar, CA
Ryan Reddy
Nuclear Imaging & Therapy · Irvine, CA
Related records
Nuclear Imaging & Therapy in California
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Imaging & Therapy
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.